SADEL
Scaffolds for alternative delivery
| Coordinatore | AZIENDA SPECIALE INNOVHUB - STAZIONI SPERIMENTALI PER L'INDUSTRIA
Organization address
address: VIA MERAVIGLI 9 B contact info |
| Nazionalità Coordinatore | Italy [IT] |
| Totale costo | 6˙510˙292 € |
| EC contributo | 4˙951˙792 € |
| Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
| Code Call | FP7-HEALTH-2011-two-stage |
| Funding Scheme | CP-FP |
| Anno di inizio | 2012 |
| Periodo (anno-mese-giorno) | 2012-01-01 - 2016-12-31 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
AZIENDA SPECIALE INNOVHUB - STAZIONI SPERIMENTALI PER L'INDUSTRIA
Organization address
address: VIA MERAVIGLI 9 B contact info |
IT (MILANO) | coordinator | 283˙933.40 |
| 2 |
INTESTINAL BIOTECH DEVELOPMENT
Organization address
address: "BOULEVARD DU PROF JULES LECLERCQ, FACULTE DE MEDECINE POLE RECHERCHE AMPHI J&K" contact info |
FR (LILLE) | participant | 975˙016.00 |
| 3 |
AFFILOGIC SAS
Organization address
address: RUE DE LA HOUSSINIERE 2 contact info |
FR (NANTES) | participant | 865˙951.00 |
| 4 |
INSTITUTO DE BIOLOGIA EXPERIMENTAL E TECNOLOGICA
Organization address
address: Av. da Republica, Quinta do Marques S/N contact info |
PT (OEIRAS) | participant | 841˙111.20 |
| 5 |
GENIBET - BIOPHARMACEUTICALS SA
Organization address
address: AVENIDA DA REPUBLICA QUINTA DO contact info |
PT (OEIRAS) | participant | 828˙796.00 |
| 6 |
UNIVERSITE DE GENEVE
Organization address
address: Rue du General Dufour 24 contact info |
CH (GENEVE) | participant | 643˙544.00 |
| 7 |
BIOMEDICAL SCIENCES RESEARCH CENTER ALEXANDER FLEMING
Organization address
address: Al. Fleming Street 34 contact info |
EL (VARI-ATHENS) | participant | 252˙320.00 |
| 8 |
FERRING PHARMACEUTICALS AS
Organization address
address: KAY FISKERS PLADS 11 contact info |
DK (KOBENHAVN) | participant | 186˙544.80 |
| 9 |
EUROPEAN CROHN S AND COLITIS ORGANISATION
Organization address
address: OLZELTGASSE 1A/2 contact info |
AT (VIENNA) | participant | 74˙576.00 |
| 10 |
ELAN PHARMA INTERNATIONAL LIMITED
Organization address
address: "TREASURY BUILDING, LOWER GRAND CANAL STREET" contact info |
IE (DUBLIN 2) | participant | 0.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'The SME-based SADEL consortium intends to develop the first generation of oral bio-therapeutics tackling disease targets in the digestive tract, by making optimal use of the Nanofitin (Nf) protein scaffold. Nf based drugs will progress through routes not travelled by antibodies while interacting with targets not modulated by chemical compounds.
Existing Nf hits against validated targets will progress to the preparation of Phase I Clinical trials in Ulcerative Colitis (UC). To achieve this, SADEL assembles a virtual biopharmaceutical company with SMEs (70%), academics, clinicians and pharma industry with all cutting-edge skills: production (including GMP), analytics, formulation, preclinical and clinical development, up to licensing.
Nfs are small (optimal tissue penetration), exhibit strong resistance to pH and human intestinal fluids (long half-life in digestive track) and their high affinity implies low effective concentration. They also demonstrate strong potential for optimizing pharmacological properties, including reducing immunogenicity.
The Nf based drugs will be administered orally, reducing the systemic exposure and avoiding the safety issues reported with systemic administration of antibodies. This requires large quantities of proteins for frequent administration. Nfs are produced in bacterial systems for which GMP-compliant processes are broadly adopted in the industry, with a low cost of goods. The resulting proteins will be formulated for optimal release at the sites of action.
The project is designed to address unmet technical challenges while avoiding external risks beyond those related to the scaffold behaviour itself. All additional elements are chosen for documented validation, from targets to evaluation protocols.
Achieving SADEL aims will solve unmet patient needs by providing affordable, safe, efficient products in a format raising comfort and compliance to treatment. It will also assess the therapeutic potential of the Nanofitin platform.'
Introduzione (Teaser)
Inflammatory bowel disease (IBD) involves chronic inflammation of all or part of the digestive tract. A new approach to IBD treatment involves development of a highly specific targeted oral drug.